Navigation Links
Huron Capital Moves Quickly To Expand O&P Business
Date:4/24/2008

Transaction marks 22nd Acquisition for The Huron Fund II L.P.

DETROIT, April 24 /PRNewswire/ -- Huron Capital Partners announced today that its portfolio company Michigan Orthopedic Services ("MOS") has acquired Koch's Orthotic / Prosthetic Services, Inc. ("Koch's"). Terms of the transaction were not disclosed. The transaction was closed less than 4 months after Huron partnered with CEO Aziz Naser to recapitalize MOS. All of Koch's employees, including CEO Marcello Girao, will continue with the business.

Based in Ann Arbor, MI, Koch's fits and fabricates orthotic and prosthetic ("O&P") devices for patients with medical conditions which require such devices to physically support a particular portion of the body (orthopedic braces) or to replace the functionality of a limb which was amputated or had a congenital birth defect (prosthetic devices).

Chris Sheeren, a Partner at Huron, stated, "We had identified Koch's as an ideal fit with MOS prior to finalizing the recap. Koch's pediatric practice is extremely strong, and its three patient care locations will help MOS expand its presence in Southeast Michigan."

Aziz Naser, CEO of MOS, added, "We are excited about bringing Koch's into the MOS family. Marcello and his team are exceptional practitioners, and we look forward to growing our businesses together."

About Huron Capital Partners LLC

Huron Capital is a leading private equity firm investing in lower middle-market companies. The firm typically invests between $10 million and $50 million in equity to sponsor buyouts of well-positioned companies having revenues up to $200 million. Through its operational approach, Huron joins forces with strong management teams at niche manufacturing, specialty service, and value-added distribution companies that can be built through acquisition and organic growth.

Huron Capital manages over $600 million in equity through three private equity funds. Since its founding in 1999,
'/>"/>

SOURCE Huron Capital Partners LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Huron Capital Caps Strong Year With Five Acquisitions In 4Q07
2. 2008 Spring Allergy Capitals Announced
3. Damian DellAnno Joins Formation Capital as Chief Operating Officer
4. Riley Hospital for Children & Capital Institute of Pediatrics become international sister hospitals
5. Atlantic Street Capital Announces First Close
6. Arsenal Capital Partners Invests in DG3
7. TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital
8. Bionovo to Present at the Cambria Capital Investor Meeting
9. Golub Capital Provides $29.5 Million GOLD Facility in Support of the Recapitalization of ExtruMed
10. Capital BlueCross Receives Prestigious Brand Excellence Award From The Blue Cross & Blue Shield Association
11. Super Model Cindy Crawford will be Honored at DKMS Linked Against Leukemia Gala on May 7th at Capitale

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , Dr. Redlener Applauds Historic Effort b...et Programs Are Lost in Final Health Care Reform ... The New England Journal of Medicine today pub...th care reform, co-authored by Irwin Redlener, M.D... National Center for Disaster Preparedness and Pro...
(Date:12/4/2009)...with knowledge of risks, many hesitate to take bre... Dec. 4 (HealthDay News) -- Worries about side eff...ican women at high risk for breast cancer are will...ase, a new study finds. , In an effort to infor... researchers at the University of Michigan Compreh...
(Date:12/4/2009)... , BOULDER, Colo., Dec. 4 ..., ON LOVE ,, Kathryn Budig, a prominent yoga te...e to healing--with a viewing of Twilight,s New Moo...nal.com: ,, http://www.elephantjournal.com/200...ournal.com: TASHI KING AND BREAST CANCER ,, el...
(Date:12/4/2009)... , JEFFERSON CITY, Mo., Dec. 4 /PRNewswire/ ...ctor Paul Crosetti, State Fire Marshal Randy Cole,...en,s fire safety program sponsored by Farmers call... safety day at the Missouri Capitol December 9. .../20080605/LATH062 ) ,, "The call for fire safet...
(Date:12/4/2009)...le who have had an ischemic stroke are at higher l... of medication can reduce that risk. One of the si...s, otherwise known as blood thinners, of which the...tudy to determine whether the use of antithromboti...r a seven-year period found that in each of the ye...
Breaking Medicine News(10 mins):Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Missouri Safety Day at the Capitol 2Health News:Are stroke survivors taking their medicine? 2
..., Dec. 3 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP...igational new,drug (IND) application to the U.S. F...und is an internally developed, orally-bioavailabl...r,patients in early 2008., "This IND submission i...
... N.Y., Dec. 3 Big A Drug Stores, Inc. has,selecte...al estate,solutions, to exclusively manage the dis...California. Big A Drug Stores, Inc. is a chain of ...gs,","Drug Fair," and "Drug Barn" (2 stores)., "W...
...APOLIS Although more and more drug advertisements...oximately $21 billion dollars that pharmaceutical ...is targeted to physicians, doctors in training (re...c. published in the December issue of the journal ...
...and PITTSBURGH, Dec. 2 Forest,Laboratories, Inc. ...ed that,Mylan has received an approvable letter fr...response to its New Drug Application (NDA) for,neb...icated that a recent inspection of,a backup manufa...
... communication with doctors and respect for role o...Y, Dec. 2 (HealthDay News) -- The death of a child...dparents, siblings, friends, even the child,s doct...ymptoms and stress of life-threatening illness -- ...
...ESTER, Ill. Hospital staff nurses who work extend...at work, or obtain less sleep are more likely to e... study published in the December 1 issue of the jo...ed from 895 full-time hospital staff nurses, who c...
Other Medicine News:Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 2Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 3Health News:Big A Drug Stores, Inc. Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium, Big A, Camelot, Drug Fair and Drug Barn 2Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 3Health News:Breaking Down Barriers to End-of-Life Care for Children 2Health News:Breaking Down Barriers to End-of-Life Care for Children 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 Dr...lts for prostate-specific antigen (PSA) recurrence...nts of biochemical recurrence rate in a Phase III ... for injection) or monthly leuprolide in prostate .... Prostate cancer patients who received FIRMAGON ...
(Date:12/3/2009)..., , NEW YORK, Dec. 3 Guid...rm, today announced the launch of their Sleep Apne...t monitors and projects trends and market share in...p Apnea Tracker captures actual patient usage for ...nited States from 15 different equipment providers...
(Date:12/3/2009)..., , SUNNYVALE, Calif., Dec. 3 /PRNewswire-..., a biopharmaceutical company focused on developin...ugs for the treatment of immune mediated diseases ...bcast and conference call on, Tuesday, December 8,...e and 8:00am Pacific Time) to discuss clinical dat...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 1Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 3ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 1ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 1CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 3
...AS, April 4, 2008 Data from five studies sponsore...d at the National Kidney,Foundation (NKF) 2008 Spr...e utilization studies involve PROCRIT(R) (Epoetin ...g utilization patterns and,costs of PROCRIT (EPO) ...s,related to chronic kidney disease (CKD) patients...
...iously-Stated Guidance Remains Unchanged, PRINCET...EDX ) today issued the following statement in resp... discontinuing its Phase 3 clinical,trial of front...LA-4,antibody (tremelimumab) compared to chemother...ey M. Nichol, M.B.Ch.B., Senior Vice President, Pr...
Other Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
HOME MULTI-DRUG TEST
SEDIPLAST ESR SYSTEM (with diluent)
SEDIPLAST ESR SYSTEM (without diluent)
Hemaprompt FG Gastric and Fecal Occult Blood Test
Medicine Products: